00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month's gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
20:34 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

FDA approves traveler's diarrhea drug from Cosmo

FDA approved Aemcolo rifamycin from Cosmo Pharmaceuticals N.V. (SIX:COPN) to treat travelers' diarrhea caused by non-invasive strains of Escherichia coli . The company said it will launch the drug next quarter. Aemcolo is a broad-spectrum,...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
15:03 , May 25, 2018 |  BC Week In Review  |  Clinical News

FDA accepts NDA for Cosmo's antibiotic

Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo (Rifamycin SV MMX) to treat travelers’ diarrhea. The PDUFA date is Nov. 16. Aemcolo is a broad-spectrum, semisynthetic, oral...
20:21 , May 18, 2018 |  BC Extra  |  Company News

FDA accepts NDA for Cosmo's antibiotic

Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo (Rifamycin SV MMX) to treat travelers’ diarrhea. The PDUFA date is Nov. 16. Aemcolo is a broad-spectrum, semisynthetic, oral...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
19:09 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Paion's remimazolam meets in Phase III trial for procedural sedation

Paion AG (Xetra:PA8) reported data from a Phase III trial in 431 patients undergoing bronchoscopy showing that procedural sedation with remimazolam (CNS 7056, ONO-2745) met the composite primary endpoint vs. both placebo and midazolam of...